Medicine
Bisoprolol and Hydrochlorothiazide 2.5 mg/6.25 mg tablet
Bisoprolol and Hydrochlorothiazide 2.5 mg/6.25 mg tablet is a generic prescription medicine for oral use, made by 12 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20° to 25°C (68° to 77°F).
Key facts
- Active ingredient (INN)
- Bisoprolol and Hydrochlorothiazide
- Brand
- Sold under the generic name
- Strength
- 2.5 mg/6.25 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 100 tablets, 500 tablets, 30 tablets and 33 more
- Manufacturers
- Unichem LaboratoriesIndiaAurobindo PharmaIndiaGlenmark PharmaceuticalsIndiaViona PharmaceuticalsIndiaZydus LifesciencesIndiaBryant Ranch PrepackANI PharmaceuticalsEdenbridge PharmaceuticalsMarlex PharmaceuticalsA-S Medication Solutions
- Origin register
- US FDA, United States
- Storage
- Store at 20° to 25°C (68° to 77°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 12 October 2010
- Identifiers
- RxCUI 854908, 854916, 854919DailyMed set ID d4243a76-516c-417e-80ba-444a21ecc688, a26bcf78-6515-4e9f-b2dc-4aaa8ec1a82c, 27d52b23-e3e2-4339-b00e-cd0fec43ffbb +11NDC 0378-0501, 70954-412, 0093-3241 +11Application ANDA075768, ANDA215562, NDA020186 +5
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 tablet, film coated in 1 bottle | 59651-678-01 | Aurobindo PharmaIndia | 21 January 2026 |
| 500 tablet, film coated in 1 bottle | 59651-678-05 | Aurobindo PharmaIndia | 21 January 2026 |
| 30 tablet, film coated in 1 bottle | 59651-678-30 | Aurobindo PharmaIndia | 21 January 2026 |
| 100 tablet, film coated in 1 bottle | 68462-878-01 | Glenmark PharmaceuticalsIndia | 26 January 2022 |
| 500 tablet, film coated in 1 bottle | 68462-878-05 | Glenmark PharmaceuticalsIndia | 26 January 2022 |
| 30 tablet, film coated in 1 bottle | 68462-878-30 | Glenmark PharmaceuticalsIndia | 26 January 2022 |
| 100 tablet in 1 bottle, plastic | 29300-187-01 | Unichem LaboratoriesIndia | 12 October 2010 |
| 500 tablet in 1 bottle, plastic | 29300-187-05 | Unichem LaboratoriesIndia | 12 October 2010 |
| 1000 tablet in 1 bottle, plastic | 29300-187-10 | Unichem LaboratoriesIndia | 12 October 2010 |
| 30 tablet in 1 bottle, plastic | 29300-187-13 | Unichem LaboratoriesIndia | 12 October 2010 |
| 100 tablet, film coated in 1 bottle | 72578-113-01 | Viona PharmaceuticalsIndia | 1 March 2023 |
| 500 tablet, film coated in 1 bottle | 72578-113-05 | Viona PharmaceuticalsIndia | 1 March 2023 |
| 30 tablet, film coated in 1 bottle | 72578-113-06 | Viona PharmaceuticalsIndia | 1 March 2023 |
| 100 tablet, film coated in 1 bottle | 70771-1760-1 | Zydus LifesciencesIndia | 1 March 2023 |
| 30 tablet, film coated in 1 bottle | 70771-1760-3 | Zydus LifesciencesIndia | 1 March 2023 |
| 500 tablet, film coated in 1 bottle | 70771-1760-5 | Zydus LifesciencesIndia | 1 March 2023 |
| 30 tablet in 1 bottle | 70954-412-10 | ANI Pharmaceuticals | 4 November 2021 |
| 100 tablet in 1 bottle | 70954-412-30 | ANI Pharmaceuticals | 4 November 2021 |
| 500 tablet in 1 bottle | 70954-412-40 | ANI Pharmaceuticals | 4 November 2021 |
| 100 tablet, film coated in 1 bottle | 42799-920-01 | Edenbridge Pharmaceuticals | 30 April 2019 |
| 500 tablet, film coated in 1 bottle | 42799-920-02 | Edenbridge Pharmaceuticals | 30 April 2019 |
| 30 tablet, film coated in 1 bottle | 42799-920-30 | Edenbridge Pharmaceuticals | 30 April 2019 |
| 100 tablet, film coated in 1 bottle, plastic | 0378-0501-01 | Mylan Pharmaceuticals | 22 February 2021 |
| 100 tablet, film coated in 1 bottle | 0093-3241-01 | Teva Pharmaceuticals | 7 August 2019 |
| 100 tablet in 1 bottle | 71335-1161-1 | Bryant Ranch Prepack | 20 March 2019 |
| 30 tablet in 1 bottle | 71335-1161-2 | Bryant Ranch Prepack | 20 March 2019 |
| 90 tablet in 1 bottle | 71335-1161-3 | Bryant Ranch Prepack | 20 March 2019 |
| 100 tablet, film coated in 1 bottle | 71335-1931-1 | Bryant Ranch Prepack | 20 August 2026 |
| 30 tablet, film coated in 1 bottle | 71335-1931-2 | Bryant Ranch Prepack | 6 August 2021 |
| 90 tablet, film coated in 1 bottle | 71335-1931-3 | Bryant Ranch Prepack | 6 August 2021 |
| 100 tablet, film coated in 1 bottle | 71335-2616-1 | Bryant Ranch Prepack | 29 May 2025 |
| 30 tablet, film coated in 1 bottle | 71335-2616-2 | Bryant Ranch Prepack | 29 May 2025 |
| 90 tablet, film coated in 1 bottle | 71335-2616-3 | Bryant Ranch Prepack | 29 May 2025 |
| 30 tablet, film coated in 1 bottle | 50090-6478-0 | A-S Medication Solutions | 16 May 2023 |
| 100 tablet in 1 bottle | 10135-740-01 | Marlex Pharmaceuticals | 1 May 2022 |
| 500 tablet in 1 bottle | 10135-740-05 | Marlex Pharmaceuticals | 1 May 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 26 March 1993 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Bisoprolol and Hydrochlorothiazide
Clinical summary
Bisoprolol and Hydrochlorothiazide is a fixed-dose combination of a thiazide diuretic and a beta-adrenergic blocker indicated in the management of hypertension. It is available as tablets for oral use. MedsAcross supplies Bisoprolol and Hydrochlorothiazide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Bisoprolol and HydrochlorothiazideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- bisoprolol fumarate and hydrochlorothiazide prescribing information (Teva Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Bisoprolol and Hydrochlorothiazide 2.5 mg/6.25 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.